Novo Nordisk told Inside Health Policy Thursday (Aug. 8) it is pursuing additional lawsuits against compounders and, though not specifically naming Hims & Hers Health Inc. (HIMS), it said it does not supply the telehealth company bulk semaglutide for compounding purposes. IHP asked Novo whether it is considering suing HIMS after the major telehealth company revealed in an earnings call Monday (Aug. 5) that its future business model is built largely on GLP-1 compounding. HIMS recently signed an...